Skip to main content
. 2016 Dec 29;8(6):10114–10135. doi: 10.18632/oncotarget.14357

Figure 7. The efficacy of IRIS inhibitory peptide against TIC tumor cells, in vivo.

Figure 7

A. The growth of established TIC/CD44+CD- MCF7 tumors grown in NSG mice following scrambled or IRIS-inhibitory intratumoral injection at the indicated times (arrows). B. Real-time QRT/PCR analysis for the expression of human Sox2 mRNA in the tumors found in the mice at day 7 (in A) post-injection of scrambled or IRIS-inhibitory peptide. C. Schematic presentation of our data combined and the hypothesis that finding and targeting the early lesions could be much more beneficial for IRISOE/TNBC patients.